B-cell maturation antigen, or BCMA, is selectively expressed when plasma cells differentiate. It is almost absent on memory and naive B cells. The maintenance of long-lived plasma cells involves the interaction between BCMA and its ligand BAFF and APRIL.
BCMA is a suitable target for cancers of plasma cells. This is because it is not induced in other major organs.
At present, dozens of BCMA-targeting therapies — such as chimeric antigen receptor T (CAR-T) cells, bi-specific antibodies and antibody-drug conjugate — are being developed and clinically tested.
At the forefront is Bluebird and Celgene’s bb2121. An amazing 80% response rate was achieved in a phase I multi-center clinical trial in multiple myeloma patients. In case these approaches are successfully established, multiple myeloma patients will benefit from a much sought-after option other than Daratumumab (anti-CD38 antibody) and Elotuzumab (anti-SLAMF7).
BAFF/APRIL and their receptors interact selectively. BCMA has the potential to interact with both APRIL and BAFF. But the affinity of the interaction between APRIL and BCMA is higher compared to that of BAFF-BCMA binding.
ACROBiosystems offers an extensive series of BCMA proteins, such as the unique biotinylated BCMA (Cat. No. BC7-H82F0) and the monomeric BCMA (Cat. No. BCA-H522y). The company also provides BCMA-related proteins like BAFF and BAFFR proteins.
Product validation data
FACS
293 cells were transfected with anti-BCMA-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-labeled human BCMA/TNFRSF17 protein, Fc tag (Cat. No. BCA-HF254, 3 μg/mL) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-BCMA-scFv) expression and FITC was used to evaluate the binding activity of FITC-labeled human BCMA/TNFRSF17 protein, Fc tag (Cat. No. BCA-HF254). Image Credit: ACROBiosystems
Human T cells were transfected with anti-BCMA CAR and cultured for 3 days. Three days post-transfection, 1e6 cells were first incubated with 50ul Biotinylated Human BCMA, Fc, Avitag (Cat. No. BC7-H82F0, 8 μg/mL), washed and then stained with PE Streptavidin and analyzed by flow cytometry. (Data are kindly provided by PREGENE Biopharma). Image Credit: ACROBiosystems
BLI
Loaded Anti-Human BCMA MAb (human IgG1) on Protein A Biosensor, can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 35.8 nM as determined in BLI assay (ForteBio Octet Red96e). Image Credit: ACROBiosystems
SPR
Anti-BCMA MAb (Mouse IgG1, the antibody was co-developed by SCT and ACRObiosystems) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in an SPR assay (Biacore T200). Image Credit: ACROBiosystems
ELISA
Immobilized Human BAFF, Fc Tag at 5 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, His, Avitag (Cat. No. BCA-H82E4) with a linear range of 15–125 ng/mL. Image Credit: ACROBiosystems
Immobilized Human APRIL, Fc Tag at 5 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, His, Avitag (Cat. No. BCA-H82E4) with a linear range of 0.6–20 ng/mL. Image Credit: ACROBiosystems
ACROBiosystems provides a wide array of readily usable biotinylated proteins through labeling techniques developed in-house. The techniques ensure minimal batch-to-batch variation and confer high bioactivity. Moreover, the company also provides FITC-labeled BAFF and BCMA proteins.
BCMA product list
Source: ACROBiosystems
| Molecule |
Cat. No. |
Species |
Structure |
Purity |
Features |
BCMA
(Biotin-labeled) |
BC7-
H82F0 |
|
|
|
|
BCMA
(FITC-Labeled) |
BCA-
HF254 |
|
|
|
|
| BCMA |
BCA-
H522y |
|
|
|
|
| BCMA |
BC7-H5254 |
 |
 |
 |
 |
Click here to learn about many more BCMA product lists.